EX-99.1

March 2015

Pieris Pharmaceuticals, Inc.

(OTC:PIRS)

The 27th Annual

ROTH CONFERENCE

Stephen Yoder

CEO

Exhibit 99.1

NON-CONFIDENTIAL

Forward Looking Statements

NON-CONFIDENTIAL

Statements in this presentation that are not descriptions of historical facts are forward-looking statements that

are based on management’s current expectations and assumptions and are subject to risks and uncertainties. In

some cases, you can identify forward-looking statements by terminology including “anticipates,” “believes,”

“can,” “continue,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,”

“should,” “will,” “would” or the negative of these terms or other comparable terminology. Factors that could cause

actual results to differ materially from those currently anticipated include, without limitation, risks relating to the

results of our research and development activities, including uncertainties relating to the discovery of potential

drug candidates and the preclinical and clinical testing of our drug candidates; the early stage of our drug

candidates presently under development; our ability to obtain and, if obtained, maintain regulatory approval of

our current drug candidates and any of our other future drug candidates; our need for substantial additional

funds in order to continue our operations and the uncertainty of whether we will be able to obtain the funding we

need; our ability to retain or hire key scientific or management personnel; our ability to protect our intellectual

property rights that are valuable to our business, including patent and other intellectual property rights; our

dependence on third-party manufacturers, suppliers, research organizations, testing laboratories and other

potential collaborators; competition in our industry; regulatory developments in the U.S. and foreign countries; as

well as those risks more fully discussed in the “Risk Factors” section of our Current Report on Form 8-K filed

with the SEC on December 18, 2014 and the other reports we file with the SEC. In light of these risks,

uncertainties and assumptions, the forward-looking statements regarding future events and circumstances

discussed in this report may not occur and actual results could differ materially and adversely from those

anticipated or implied in the forward-looking statements. You should not rely upon forward-looking statements as

predictions of future events. The forward-looking statements included in this presentation speak only as of the

date hereof, and except as required by law, we undertake no obligation to update publicly any forward-looking

statements for any reason after the date of this presentation to conform these statements to actual results or to

changes in our expectations.

R&D company developing first-in-class biologics

Built on cutting-edge Anticalin®

technology

Highly differentiated next generation therapeutic proteins

Multispecifics, Inhaled Delivery, Tunable Kinetics

Superior drug-like properties

Strong patent position and no 3

party IP identified to date for FTO

Clinical activity, lack of immunogenicity in cancer patients

Proprietary pipeline in Immuno-Oncology, Immunology,

Anemia and Respiratory

Proven track record for successful collaborations with Pharma

Pieris Pharmaceuticals, Inc. –

The Corporation (OTC:PIRS)

NON-CONFIDENTIAL

Protected by strong IP

Strong pipeline validated by clinical data

Solid Financial Position

$54M in total revenues

$82.6M total capital raised

Went public in Dec 2014 through reverse merger

Raised $13.6M

Straight common stock

$18M in cash as of Dec 2014 year end

Major shareholders include Ally Bridge Group, Forbion Capital, Gilde, GLSV,

Lombard

Odier,

Montrose

Capital,

Novo

Nordisk,

OrbiMed

Advisors,

Sphera

Funds and Zydus Cadila

CEO, CSO, Head of Discovery, Head of BD

all formerly at MorphoSys

Potential to repeat German Biotech MorphoSys success story:

MorphoSys currently with >20 clinical programs, multiple

high-value pharma partnerships, approx. $2bn market cap

Pieris Pharmaceuticals, Inc. –

The Corporation (OTC:PIRS)

NON-CONFIDENTIAL

Highly experienced international leadership team

Experienced Management Team

Stephen

Yoder

Ulrich

Moebius

Christine

Rothe

Shane

Olwill

Eckhard

Niemeier

Darlene

Deptula

Title

CEO

CSO

Head

Discovery

Head

Dev

Head

CFO

Education

BS/BA

PhD

Post doc

PhD

Post doc

PhD

Post doc

MBA

Prior

Experience

NON-CONFIDENTIAL

NON-CONFIDENTIAL

2010

2011

2012

2013 & 2014

value

Ph I study with VEGF-A program initiated (PRS-050)

In vivo POC on cMet program (PRS-110)

Broad Collaboration with Sanofi Group

In vivo POC and €

6M grant for hepcidin

program (PRS-080)

Alliance with Daiichi Sankyo

PRS-050 Ph I study successfully completed

Zydus Cadila & Stelis

Alliances

Milestone payments

from Daiichi

Expansion of Sanofi Partnership

& milestone payment

Significant Achievements

2010 to 2014

NON-CONFIDENTIAL

mAbs

–

Fast

Growing

Segment

Anticalins –

Differentiated Fast-Followers

Rx sales growth p.a. 2010-16

by drug type

Source: Datamonitor

+ 8.2%

+ 4.6%

+ 2.2%

+/-

0.0%

Monoclonal

Antibodies

(mAbs)

are

highly

successful

drugs

showing

very

high

sales

growth

within

prescription

pharmaceuticals

Anticalins share many

of the beneficial properties

of mAbs and are at the

same time highly

differentiated

Formatting

flexibility

for

multispecific

drugs

Alternative

delivery

routes

(e.g.

inhaled)

due to size and biophysical properties

Tunable

kinetics

match

biological

need

Lower

COGS

due

bacterial

expression

Anticalin

NON-CONFIDENTIAL

Human Lipocalins –

Scaffold for

Novel Anticalin Therapeutics

High-affinity (pM)

Anticalin bound to

Medium

target

Large

target

Human lipocalin

“template”

Small

target

Human, natural

binding proteins

Low molecular

weight

(~1/8 of mAb size)

Extracellular

Non-immunogenic

Very stable “cup-

like”

structure

Highly diverse libraries

(>10

) of potential drug

candidates

Highly automated selection

and screening technology

(phage display)

Deep protein engineering

know-how to yield ideal

drug candidates

NON-CONFIDENTIAL

Pure Anticalin formats

Tetracalin

mAb-Anticalin formats

Fc-Anticalin formats

Anticalin

Tricalin

Duocalin

Molecules designed for optimal target engagement and drug like properties

Binding site geometry can be adjusted to biological need

Choice –

Anticalins Meet the

Industry Demand for Multispecifics

NON-CONFIDENTIAL

Commercialization Strategy

Multiple Shots on Goal: Partnered & Proprietary

Pieris selects target, funds all costs

Shared investment, shared ownership

Partner selects target, funds all costs

Alternative mechanism to advance several programs

in a proprietary-like fashion

Retain commercialization rights in major markets

Immuno-oncology, anemia, respiratory: strong networks

High barriers to entry: e.g. IP, multispecifics, inhalation

Industry validation

Significant cash flow upfront and milestone payments

Fully

Proprietary

Co-Dev

Fully

Partnered

PRS-080

Hepcidin

Anemia

PRS-060

IL4Ra

Asthma

PRS-300

multiple

PRS-050

VEGF-A

Oncology

Discovery

Preclinical

Phase 1

Phase 1b

Phase 2

Target(s)

1°

Indication

Pieris to fund

Partner to fund

PRS-110

cMet

Oncology

PRS-NN

n.d.

PRS-NN

n.d.

Ophthalmology

PRS-NN

n.d.

Ophthalmology

Sanofi Group

n.d.

Sept 2010 Initiation

Daiichi Sankyo

n.d.

April 2011 Initiation

n.d. = not disclosed

Pipeline: Today & Planned

Progression Through End of 2016

Status Today

NON-CONFIDENTIAL

Validating Collaborations

Partner

Overview

Financials

Comments

Multispecifics drug

discovery collaboration –

2010

> 50M €

potential for each

program; royalties

2 milestone payments to date

Multispecifics project

handover achieved 4Q14

Two-program drug

discovery collaboration –

2011

> 100M €

potential for each

program; royalties

5 milestone payments to date

Several potential milestone

payments 2015-17

Co-development

collaboration, incl. cMet

oncology

–

2013

Funded through clinical POC

Pieris retains major markets

Retained strategic oversight

Minimal investment through

early clinical development

Co-development in

ophthalmology –

2013

Funded through first patient

study

Pieris retains 50% WW

Anticalin program in

ophthalmology

–

2009

$10M upfront

Program handed off to

Allergan

NON-CONFIDENTIAL

PRS-080: Intended to Reverse Hepcidin-

Mediated Functional Iron Deficiency

PRS-080 reverses hepcidin-mediated anemia by mobilizing iron

trapped in the body’s iron storage cells

Addresses patients unresponsive to ESA and iron therapies

PK profile of PRS-080 designed to match hepcidin biology

Iron

Ferroportin

Inflammation

Hepcidin

PRS-080

NON-CONFIDENTIAL

NON-CONFIDENTIAL

PRS-080: Effective in vivo –

Currently in Phase 1

Demonstrated efficacy and safety in cynos

Single-dose serum iron response

Increased reticulocyte hemoglobin after

multiple doses

No adverse events in GLP tox

First-in-man study initiated December 2014

Single-dose escalation in HVs (n=48)

Endpoints:

Safety, MTD, PK, immunogenicity

Target engagement

PD effects: serum iron, ferritin, transferrin

saturation, reticulocyte count, hemoglobin

Final cohort of subjects planned mid 2015

Reporting of results expected 2H 2015

Serum iron response in cyno following

single i.v. administration

Pre-dose

Day 30

i.v. 150 mg/kg

Day 30

s.c. 20 mg/kg

Funded through Ph I by ongoing €

6M EU grant

Elevation of reticulocyte Hg in cyno

following repeated administration

Time [h]

100

10 mg/kg PRS-080

10 mg/kg NGAL wt

PRS-080 in Chronic Kidney Disease

Market Opportunity

Sources:

USRDS 2014 Annual Data Report (2012 numbers): Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the U.S

ESRD Patients in 2011 –

A Global Perspective, Fresenius Medical Care; Artisan Healthcare Consulting market research study

Hemodialysis

Patients

(Total 1.9M Worldwide)

anemia

18%

Anemic

82%

Hemodialysis Patients

with Anemia

(Total 1.6M Worldwide)

FID

24%

No FID

76%

Target Functional

Iron-Deficient (FID)

population:

U.S. 80,000

EU 61,000

JP 57,000

ROW 186,000

Estimated yearly

treatment costs:

~ $5,000 -

$10,000

Treating FID anemic

HD patients with

PRS-080 has large

commercial potential

NON-CONFIDENTIAL

NON-CONFIDENTIAL

PRS-060 –

First-in-Class Inhaled

Biologic Targeting IL4Ra

Strong target validation & biomarker availability

IL4Ra a key mediator in Th

pathway disorders including asthma

IL4Ra mediates IL4 and IL13 signaling

Patient

selection

with

pathway

now

straight-forward

IL4/13 mAbs (e.g. dupilumab) with strong efficacy in Phase 2b

Validated biomarkers (e.g. FeNo) allow for early clin. read-out

NON-CONFIDENTIAL

Clear differentiation from systemic mAbs

Broader

therapeutic

index

Low

systemic

exposure

may

lead

better

side effect profile long-term (e.g. role of Th2 in metabolic balance)

convenient

Inhalation

preferred

over

s.c.

injections

flexible

Daily

dosing

may

allow

combination

with

SoC

Micro-dosing

Lower

COGS

May

allow

reaching

broader

patient

populations

Pulmonary Delivery of PRS-060

Effective in vivo & Feasible Formulation

Inhibition of IL13-induced eotaxin expression following

pulmonary administration of PRS-060

Early onset of inhibition and

durability of effect up to 24h

post pulmonary administration

Time of single treatment prior to IL-13 challange

SEC

Diagrams

Device

Nebulizer

Spray Dryer

NON-CONFIDENTIAL

0.2

0.4

0.6

0.8

1.2

Nebulization and spray drying

feasibility demonstrated

Appropriate particle size

No aggregation

Full functional activity

High Yield

NON-CONFIDENTIAL

PRS-060 in Asthma

Market Opportunity

Major Markets: U.S., EU, Japan, Brazil, Russia, India, China

Asthma

Patients

(Total

195M

Major

Markets

)

Mild/

Controlled

84%

Mod./Severe

uncontrolled

16%

Moderate/Severe

uncontrolled Patients

(Total 32M in Major Markets)

Th2

elevated

60%

No Th2

elevation

40%

Target Th2 elevated

Asthma population:

19M in Major

Markets

Estimated yearly

treatment costs:

~ $10,000 -

$15,000

Treating Th2-

elevated

uncontrolled

Asthma patients

with PRS-060 is a

blockbuster

opportunity

Source:

Artisan Healthcare Consulting market research study

NON-CONFIDENTIAL

NON-CONFIDENTIAL

PRS-300 Series –

Addressing Two

High Unmet Needs in Oncology

Potential benefits of tumor-localized engagement of immune system:

Increased efficacy in patients unresponsive to targeted therapies

Enhanced tolerability with reduced on-target “off-tumor”

effects

mAb component drives

therapeutic to tumor

Anticalin engages the

immune system “locally”

Tumor

Cell

T cell

Tumor-targeting

mAb

Immune system-

targeting Anticalin

NON-CONFIDENTIAL

Mode of Action:

NON-CONFIDENTIAL

PRS-300 Series

Costimulatory T cell Engagement

Costimulatory T cell

engagement in the

tumor micro-

environment to

maintain

T cell receptor-

mediated tumor

antigen specificity

NON-CONFIDENTIAL

TNFRS

Receptor

No activation

in periphery

T cell

receptor

MHC-

peptide

T Cell

Costimulatory

signal

Primary

TcR signal

Activation

Tumor Cell

Clustering on

tumor cells

NON-CONFIDENTIAL

PRS-300 Series

Differentiates from Current IO Approaches

Approach

Tumor-

targeted

activation

TcR-

mediated

specificity

Toxicity

Delivery

Agonistic

mAbs

Yes

Low to

significant

Injection

BiTE

Yes

Observed

Slow infusion

CAR-T

Yes

Observed

Individualized

adoptive therapy

PRS-300

Yes

Expected low

Injection

NON-CONFIDENTIAL

NON-CONFIDENTIAL

Differentiated Immuno-Oncology

Drugs Have Blockbuster Potential

Source: Citi Research

Checkpoint agents have a market potential in excess of $20bn by 2021

Consensus forecasts in

initial indications

Price of therapy per patient set to

increase due to migration to

checkpoint combination therapy

Combination strategies with chemo/

radio/mAbs/vaccines/cryo likely to

expand potential indications

x1.5

x1.3

Duration of immunotherapy likely

to expand given anticipated

improvements in progression-

free and overall survival

NON-CONFIDENTIAL

NON-CONFIDENTIAL

Anticalin Intellectual Property –

Safe & Sound

Exclusivity

Drug class protected through 2020s

Controlled patent filings and prior art

enable broad follow-on protection

Unique IP for each program

Freedom to Operate

No third party IP identified to date for

FTO on platform or therapeutic programs

Program

(Target)

CoM Patent

Term

cMet

2030

Hepcidin

2031

IL4Ra

2031

300 Series

(IO)

2035+

NON-CONFIDENTIAL

NON-CONFIDENTIAL

1H15

2H15

2016

value

Key preclinical milestones for first Daiichi & Sanofi programs

Ph I initiated for Hepcidin

Several partnered Anticalins in Ph I

Ph I completed for Hepcidin

IND-readiness for IL4Ra

New R&D partnership

Ph I completed for IL4Ra

Corporate Objectives 2015-2017

Ph Ib/IIa compl. for Hepcidin

2017

IND-readiness for IO

NON-CONFIDENTIAL

NON-CONFIDENTIAL

30-Month Projected Pipeline

Progression

PRS-080

PRS-060

PRS-300

2015

2016

2017

Phase I

GLP / GMP

Phase Ib/IIa

Phase Ia/Ib

GLP / GMP

In vivo POC

Lead Opt

Phase IIb

GLP / GMP

Phase I

GLP / GMP

Phase I

GLP / GMP

Phase I

GLP / GMP

Phase I

GLP / GMP

Phase I

In vivo POC

NON-CONFIDENTIAL

NON-CONFIDENTIAL

Corporate & Financial Summary

Company founded in 2001

OTCBB: PIRS, December 2014, raised $13.6M

Total capital raised $82.6M

Major shareholders include Ally Bridge Group, Forbion Capital,

Gilde, GLSV, Lombard Odier, Montrose Capital, Novo Nordisk,

OrbiMed Advisors, Sphera Funds and Zydus Cadila

Revenues –

$54M ($40M licensing and $14M grant revenue)

At September 30, 2014 (9 months)

Net Loss

$ 5.7M

Cash & Cash Equivalents

$ .9 M

Debt

$ 5.1M

Shares Outstanding Fully Diluted: 33,021,882

Includes 3.2M option pool & 542,360 warrants

Validation through strategic partnerships and collaborations

Sanofi, Daiichi Sankyo, Zydus, Stelis, Allergan

NON-CONFIDENTIAL

NON-CONFIDENTIAL

Investment Highlights

Human PoC achieved with Anticalin platform

Novel therapeutic proteins

Superior drug-like properties

Validation through strategic partnerships and collaborations

Sanofi, Daiichi Sankyo, Zydus, Stelis, Allergan

Several differentiated proprietary and partnered drug candidates

advancing towards or through clinical development

Potential for rich news flow in 2015

Milestone payments; clinical data; new partnerships

Proven management team and highly regarded Board of Directors

NON-CONFIDENTIAL

NON-CONFIDENTIAL

Pieris Pharmaceuticals, Inc.

Lise Meitner Strasse 30

85354 Freising

Germany

Tel.: +49 (0) 8161 1411 400

Fax: +49 (0) 8161 1411 444

info@pieris.com

www.pieris.com

NON-CONFIDENTIAL